Format

Send to

Choose Destination
See comment in PubMed Commons below
Anticancer Res. 2012 Aug;32(8):3339-44.

Clinical significance of circulating tumor cells and free DNA in non-small cell lung cancer.

Author information

1
Department of Respiratory Medicine, Toho University Omori Medical Center, 6-11-1 Omori-Nishi, Ota-ku, Tokyo 143-8541, Japan. kazutoshiisobe@aol.com

Abstract

AIM:

This pilot study assessed correlations between circulating tumor cells (CTCs) and circulating free DNA (cfDNA) of metastatic non-small cell lung cancer (NSCLC) after acquisition of resistance to epidermal growth factor receptor tyrosine kinase inhibitors.

PATIENTS AND METHODS:

CTCs were counted using the CellSearch system (Veridex). cfDNA was analyzed for EGFR mutation status by the Cycleave real-time PCR assay.

RESULTS:

Twenty-four patients participated in this study. CTCs were detected in 8 of 24 cases (33.3%), at a mean of 2.6 CTCs per 7.5 ml blood (range: 1-24). EGFR mutations in cfDNA were detected in 6 out of 24 cases (25%). The EGFR mutation detection rates in cfDNA were significantly higher in patients with ≥ 2 CTCs per 7.5 ml (100%) than in those with <2 CTCs per 7.5 ml (10%) (p=0.0001).

CONCLUSION:

The presence of CTCs was correlated with the positivity of EGFR mutation in cfDNA.

PMID:
22843912
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Support Center